Megan Hollasch

A study showed Cabometyx improved time before disease progression in advanced digestive NETs compared with placebo.

Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in patients with chronic myeloid leukemia.

Fotivda monotherapy may show better outcomes in second-line therapy than the combination of Opdivo and Fotivda in metastatic kidney cancer.

Patients with metastatic, castration-resistant prostate cancer saw significant benefits from the combination of Xofigo and Xtandi.

Researchers identified five traits that may increase a person’s chance of experiencing polycythemia vera progression.

Lorbrena demonstrated longer progression-free survival and improved time to intracranial progression, compared with Xalkori in ALK-positive non-small cell lung cancer.

The addition of Lynparza to presurgical chemotherapy did not improve outcomes for patients with basal-like BRCA wild-type triple-negative breast cancer.

Patients with clear cell renal cell carcinoma had improved overall survival when treated with adjuvant Keytruda compared to placebo.

Patients with chemotherapy-naïve, HER2-low hormone receptor-positive metastatic breast cancer experienced antitumor activity via combination therapy with Arimidex or Faslodex plus Enhertu, according to data from the phase 1b DESTINY-Breast08 trial.

The addition of Keytruda to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

Adding Keytruda to EBRT and chemotherapy, followed by brachytherapy, improved progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

After two years of follow-up, patients with advanced melanoma treated with Opdivo and Opdualag continued to obtain a survival benefit compared with Opdivo alone.

Cabometyx, Opdivo and Yervoy led to high disease control rates across different subgroups of patients with kidney cancer, research showed.

Erleada showed promising results in patients with metastatic castration-sensitive prostate cancer when compared with Xtandi and Zytiga.

Patients with myeloma who are being treated with Tecvayli must discuss symptoms of cytokine release syndrome with their providers as soon as they happen.